首页 > 抗体蛋白 > 抗体
Brilliant Violet 605™ anti-mouse/human CD45R
产品名称:
Brilliant Violet 605™ anti-mouse/human CD45R
产品类别:
抗体
产品编号:
103243
产品应用:
103243
[价格]
规格 价格 库存
125µL ¥ 2926 1

产品详情

Product Details

Verified Reactivity
Mouse, Human
Reported Reactivity
Cat
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Abelson murine leukemia virus-induced pre-B tumor cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605? under optimal conditions.
Concentration
?g sizes: 0.2 mg/mL
?L sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the ?g size, the suggested use of this reagent is ≤0.5 ?g per million cells in 100 ?l volume. For immunofluorescent staining using the ?l size, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605? excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605? is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet?.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Clone RA3-6B2 has been described to react with an epitope on the extracellular domain of the transmembrane CD45 glycoprotein which is dependent upon the expression of exon A and specific carbohydrate residues. Additional reported applications (for the relevant formats) include: immunoprecipitation1, in vitro and in vivo modulation of B cell responses2-4, immunohistochemistry of acetone-fixed frozen sections and formalin-fixed paraffin-embedded sections5,6, and spatial biology (IBEX)14,15.

Application References

(PubMed link indicates BioLegend citation)
  1. Coffman RL. 1982. Immunol. Rev. 69:5. (IP)
  2. George A, et al. 1994. J. Immunol. 152:1014. (Activ)
  3. Asensi V, et al. 1989. Immunology 68:204. (Activ)
  4. Domiati-Saad R, et al. 1993. J. Immunol. 151:5936. (Activ)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Monteith CE, et al. 1996. Can. J. Vet. Res. 60:193. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Chang C L-T, et al. 2007. J. Immunol. 178:6984.
  9. Fazilleau N, et al. 2007. Nature Immunol. 8:753.
  10. Lang GL, et al. 2008. Blood 111:2158. PubMed
  11. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  12. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  13. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  14. Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
  15. Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed
Product Citations
  1. Yu‐Han Chang et al. 2017. Immunity. 47(5):943-958 . PubMed
  2. McNamara HA, et al. 2020. Cell Host Microbe. 572:28. PubMed
  3. Kim EH, et al. 2020. Elife. 9:00. PubMed
  4. Wang KC, et al. 2018. Immunohorizons. 2:407. PubMed
  5. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
  6. Sangesland M, et al. 2020. Immunity. 51(4):735-749. PubMed
  7. Chen S, et al. 2022. Cancer Discov. :. PubMed
  8. Chen J, et al. 2022. Nat Commun. 13:6759. PubMed
  9. Treger RS, et al. 2020. Immunity. 50(2):334-347.e9.. PubMed
  10. Wang H, et al. 2022. Curr Protoc. 2:e446. PubMed
  11. Best SA, et al. 2018. Cell Metab. 27:935. PubMed
  12. Kim SP, et al. 2021. Cell Reports. 36(9):109626. PubMed
  13. Rios D, et al. 2015. Mucosal Immunol. 101038/mi. PubMed
  14. Lopez DA, et al. 2022. Cell Rep. 41:111677. PubMed
  15. Stump CT, et al. 2021. Open Biol. 11:210245. PubMed
  16. Viant C, et al. 2021. J Exp Med. 218:. PubMed
  17. Poon E, et al. 2017. J Immunother Cancer. 10.1186/s40425-017-0268-8. PubMed
  18. Jacque E, et al. 2015. J Exp Med. 212:883. PubMed
  19. Soni C, et al. 2020. Immunity. 52(6):1022-1038.e7. PubMed
  20. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  21. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  22. Mittal A, et al. 2021. Sci Rep. 11:10731. PubMed
  23. Biram A, et al. 2020. Bio Protoc. e3562:10. PubMed
  24. Chatterjee D, et al. 2021. Cell Reports. 35(2):108996. PubMed
  25. Andersen L, et al. 2020. Cell Reports. 29(13):4447-4459.e6.. PubMed
  26. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  27. Zhou X, et al. 2021. Cell Reports. 34(1):108601. PubMed
  28. Cunha LD et al. 2018. Cell. 175(2):429-441 . PubMed
  29. Clancy–Thompson E, et al. 2019. EMBO J. 38:e101260. PubMed
  30. Baglaenko Y, et al. 2016. PLoS One. 11: 0150515. PubMed
  31. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  32. Coley WD et al. 2018. F1000Research. 2018 Mar 14 [revised 2018 Jan 1] 0.5125. PubMed
  33. Xu JL, et al. 2022. Front Pharmacol. 13:911663. PubMed
  34. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  35. Schuh E, et al. 2017. J Immunol. 198:3081. PubMed
  36. Viant C, et al. 2020. Cell. 183:1298. PubMed
  37. Heyde A, et al. 2021. Cell. 184(5):1348-1361.e22. PubMed
  38. Viant C, et al. 2021. STAR Protocols. 2(2):100389. PubMed
  39. Finkin S et al. 2019. Immunity. 51(2):324-336 . PubMed
RRID
AB_11203907 (BioLegend Cat. No. 103243) AB_2563312 (BioLegend Cat. No. 103244)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

B cells, T cell subset, NK cell subset

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4
Cell Type
B cells, NK cells, T cells
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID
19264 View all products for this Gene ID 5788 View all products for this Gene ID
UniProt
View information about CD45R on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线